Final cohort opens for recruitment in the CL04 theranostic trial in paediatric neuroblastoma
Sydney, Australia 26 July 2023 Highlights Cohort 3 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE at a dose of 275MBq/kg body weight. Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as planned. Recruitment of cohort 4 is open at clinical sites in the US at…